Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,130,759
  • Shares Outstanding, K 49,010
  • Annual Sales, $ 80 K
  • Annual Income, $ -349,140 K
  • 36-Month Beta 1.54
  • Price/Sales 39,721.00
  • Price/Cash Flow 0.00
  • Price/Book 10.33

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.68 +1.66%
on 11/14/17
79.60 -19.95%
on 10/23/17
-13.78 (-17.78%)
since 10/20/17
3-Month
62.68 +1.66%
on 11/14/17
86.26 -26.13%
on 10/13/17
-7.48 (-10.51%)
since 08/21/17
52-Week
33.23 +91.75%
on 11/23/16
99.45 -35.93%
on 07/28/17
+27.41 (+75.49%)
since 11/21/16

Most Recent Stories

More News
Today's Research Reports on Trending Tickers: Ekso Bionics and Clovis Oncology

NEW YORK, NY / ACCESSWIRE / November 20, 2017 / U.S. markets closed in the red Friday, with the Dow Jones and S&P 500 posting their second consecutive weekly loss, as concerns regarding President Trump's...

EKSO : 3.26 (+11.64%)
CLVS : 63.77 (-0.17%)
Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences - Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Pure Storage, Inc. (NYSE:PSTG),...

PSTG : 17.85 (+1.71%)
CTLT : 38.88 (+0.99%)
CLVS : 63.77 (-0.17%)
BYD : 30.60 (+0.59%)
HALO : 18.82 (+0.64%)
BGC : 20.80 (+0.24%)
Corporate News Blog - AVEO and EUSA Pharma Report Positive Results for TiNivo Study of Tivozanib and Nivolumab

Research Desk Line-up: Clovis Oncology Post Earnings Coverage

AVEO : 3.05 (-1.29%)
CLVS : 63.77 (-0.17%)
Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss

Clovis (CLVS) witnessed narrower year-over-year loss in the third quarter. Also, the company's revenues missed estimates. Rubraca adoption slower.

AZN : 33.73 (+1.05%)
CLVS : 63.77 (-0.17%)
TSRO : 86.23 (+3.22%)
BMY : 61.44 (+1.05%)
Clovis Oncology Announces Third Quarter 2017 Operating Results

--Submission of a supplemental New Drug Application (sNDA) for rucaparib as maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer completed in early October

CLVS : 63.77 (-0.17%)
Clovis Oncology, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 1, 2017 / Clovis Oncology, Inc. (NASDAQ: CLVS) will be discussing their earnings results in their Q3 Earnings Call to be held on November 1, 2017 at 4:30 PM Eastern...

CLVS : 63.77 (-0.17%)
Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?

With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.

CLDX : 2.89 (+1.05%)
CLVS : 63.77 (-0.17%)
SNDX : 8.46 (-0.70%)
BMY : 61.44 (+1.05%)
What to Expect from Keryx (KERX) This Earnings Season?

Keryx (KERX) will focus on the label expansion of its only approved drug, Auryxia, during the third-quarter 2017 earnings call.

AGEN : 3.72 (+1.92%)
KERX : 4.83 (-1.83%)
CLVS : 63.77 (-0.17%)
ACAD : 27.57 (-0.47%)
What's in Store for Intrexon (XON) This Earnings Season?

Intrexon (XON) will remain focused on its performance along with other developmental updates in the third quarter of 2017.

AGEN : 3.72 (+1.92%)
XON : 12.39 (-0.88%)
CLVS : 63.77 (-0.17%)
FCSC : 1.44 (-4.00%)
Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?

Spectrum Pharmaceuticals' (SPPI) Folotyn and Evomela drugs are expected to drive third-quarter sales. The company is progressing well with its pipeline candidates.

SPPI : 20.00 (+4.60%)
MYGN : 32.87 (+0.64%)
CLVS : 63.77 (-0.17%)
SNDX : 8.46 (-0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

2nd Resistance Point 66.23
1st Resistance Point 65.06
Last Price 63.77
1st Support Level 62.98
2nd Support Level 62.07

See More

52-Week High 99.45
Fibonacci 61.8% 74.15
Fibonacci 50% 66.34
Last Price 63.77
Fibonacci 38.2% 58.53
52-Week Low 33.23

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart